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ScienceDirectThe headline success of targeting GPCRs in human diseases
has masked the fact that many GPCR drug discovery
programmes fail. This is despite a substantial increase in our
understanding of GPCR pharmacology that has provided an
array of ligands that target both orthosteric and allosteric sites
as well as ligands that show stimulus bias. From this plethora of
pharmacological possibilities, can we design ligand properties
that would deliver maximal clinical efficacy with lowest toxicity?
This may be achieved through animal models that both validate
a particular GPCR as a target as well as revealing the signalling
mechanisms that underlie receptor-mediated physiological
and clinical responses. In this article, we examine recent novel
transgenic models being employed to address this issue.
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Introduction
Given that G-protein coupled receptors (GPCRs)
represent a large and diverse cell surface family that impact
on nearly every physiological and pathophysiological
scenario, coupled to the fact that small molecule ligands
can be readily designed that either inhibit (antagonists) or
activate (agonists) these receptors, the rational for targeting
GPCRs in a range of human diseases appears well justified
[1]. A cursory analysis would support this conclusion with
approximately a quarter of the drugs currently on the
market having modes of action via targeting GPCRs
[2,3,4]. Despite this apparent success, and the discovery
of ‘block-buster’ drugs yielding many billions of dollars of
annual sales [5], the promise held by GPCRs as targets in
drug discovery has not fully materialised. Thus, of the
Open access under CC BY-NC-ND license.www.sciencedirect.com >390 non-olfactory GPCRs in the human genome [6] only
15% have been targeted successfully by the pharmaceu-
tical industry [2,4]. This is despite many decades of
intense effort, which has seen a dramatic increase in our
knowledge of the signalling mechanisms and molecular
pharmacology of these receptors together with the recent
revelation of the atomic structures and mechanisms of
receptor ligand interactions revealed by molecular
dynamic simulations. The question of why GPCRs have
not been more fruitfully targeted is complex, but one
important factor relates to the fact that many drugs fail
in phase II and III clinical trials due to lack of clinical
efficacy [7,8]. This raises questions not only about the
suitability of the model systems used to validate GPCR
targets but also about whether we know enough about the
in vivo modes of action of GPCRs to design ligands with the
pharmacological properties needed to deliver the desired
physiological/therapeutic response? These questions are
particularly relevant in an era that has seen an explosion in
our understanding of molecular pharmacology, which has
driven an increasing plethora of pharmacological possibi-
lities from orthosteric ligands of various flavours to a com-
plex array of allosteric modulators. In this article, we will
examine one possible way forward, where, by bringing
together molecular pharmacological approaches, structure
based drug design and novel in vivo animal models an
integrated knowledge base can be assembled that if cor-
rectly applied might inform more effective drug develop-
ment aimed at improving the success rate of GPCR-based
drug discovery programmes.
The sophistication of GPCR molecular
pharmacology
One of the key characteristics of GPCRs is that small
molecule ligands can be designed to interact with the
natural ligand binding site, the so-called orthosteric site.
The application of high-throughput screening (HTS) on
recombinant receptors expressed in vitro, together with
medicinal chemistry to develop hit molecules, has
resulted in the generation of ligands with varied
pharmacology, including full and partial agonists,
antagonists and inverse agonists [9]. In many instances,
the pharmacology has been extended to include ligands
that interact with sites outside the orthosteric sites.
Binding to these sites, termed allosteric sites, can
directly drive the receptor into an active or inactive
conformation (i.e. allosteric agonists or antagonists)
[10]. Alternatively, allosteric ligands can change the
receptor conformation in a manner that influences the
affinity of ligands for the orthosteric sites and/or thatCurrent Opinion in Cell Biology 2014, 27:117–125
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stream signalling pathways. Thus, allosteric ligands can
affect the activity of the natural ligand by being a
positive allosteric modulator (PAMs), a negative allo-
steric modulator (NAMs) or silent allosteric modulators
(SAMs) [10].
This array of pharmacology is exemplified by ligands to
the muscarinic receptor family that consists of five re-
ceptor subtypes that are all activated by the natural
ligand acetylcholine [11]. These receptor subtypes
are activated by full (acetylcholine and methacholine)
and partial (arecoline and pilocarpine) orthosteric ago-
nists in a manner that is not subtype selective due to the
high level of conservation at the orthosteric site [12,13].
In addition, there is an array of allosteric modulators to
this receptor family which target divergent sites which
allows for subtype selectivity [14–16]. Thus, there are
both positive and negative allosteric modulators that
target selective muscarinic receptor subtypes. For
example, benzyl quinolone carboxylic acid (BQCA) is
a positive allosteric modulator to the M1-muscarinic
receptor [17]. This is one of the most robust PAMs
described to date [18] for any GPCR subtype, increasing
the affinity of acetylcholine specifically at the M1-
muscarinic receptor by a factor of more than 100 [18].
Importantly, BQCA does not only show positive co-
operativity  towards acetylcholine binding but also
appears to have intrinsic agonist activity which is
revealed at high concentrations of BQCA in assay sys-
tems showing high sensitivity, such as pERK1/2 assays
[18]. Thus, for the M1-muscarinic receptor, there is an
array of both orthosteric and allosteric ligands with
defined pharmacology which can be progressed in drug
discovery programmes where targeting this receptor
subtype has been determined as having potential thera-
peutic benefit [19–21]. Such programmes are currently
aimed at treating cognitive impairment in neurodegen-
erative disease such as Alzheimer’s disease and in psy-
chiatric illness such as schizophrenia [19]. This situation
is not, however, unique to the M1-muscarinic receptor
but can be played out for many other, if not all, receptor
systems considered as targets in disease [10,22].
In light of this explosion in pharmacological possibilities,
pharmacologists face a fundamental problem in having to
decide what type of pharmacology is most suitable to treat
a particular disease. This is made more complex by the
concept of functional selectivity, also termed ligand or
stimulus bias [23,24], whereby the signalling outcome of
a receptor can be modulated differentially by different
ligands. Thus, a receptor that couples to three signalling
pathways such as calcium mobilisation, pERK signalling
and Rho-activation might be stimulated by ligand ‘A’ that
drives all three pathways in a manner equivalent to the
endogenous ligand and hence shows no stimulus bias. In
contrast, another ligand ‘B’ might preferentially driveCurrent Opinion in Cell Biology 2014, 27:117–125 calcium signalling and therefore be described as showing
Gq/11-protein bias. Whereas a third ligand ‘C’ might show
receptor phosphorylation/arrestin bias thereby preferen-
tially activating pERK signalling (Figure 1). In this
scenario, ligands A, B and C act at the same receptor
but might have very different physiological impacts based
on their different stimulus bias (Figure 1). This may be
very important therapeutically since one signalling arm
might lead to a therapeutically beneficial outcome and
the other lead to an adverse response [25,26]. Therefore,
from a therapeutic point of view, one would want to
design a ligand to be biased towards signalling that drives
therapeutic benefit and away from pathways that mediate
toxic/adverse outcomes.
Thus, we are left with a wide array of pharmacological
possibilities, from full and partial orthosteric ligands, to
positive and negative allosteric modulators; layered on to
this is the fact that both orthosteric and allosteric ligands
can show stimulus bias. The question now, therefore, is
what type of pharmacology is desired to address any one
therapeutic situation? One possible way of addressing this
question is the use of novel animal models in combination
with ligands with defined pharmacology.
Novel animal models to determine modes of
action of GPCRs
Gene knockout studies have contributed hugely to our
understanding of the physiological role of GPCRs [27,28].
However, it has become clear that more sophisticated
transgenic animal models are required to determine with
precision the receptor-mediated signalling pathways that
underlie physiological GPCR responses. One recent
advance in this area is the utilisation of chemical genetic
approaches which involve the expression of a mutant form
a receptor that is unable to be activated by the endogen-
ous ligand but instead can be activated by an otherwise
inert chemical; the first of such receptors was called a
‘Receptor Activated Solely By Synthetic Ligand’
(RASSLs). Although useful to define the potential phys-
iological impact of receptors such as the kappa-opioid
receptor [29,30,31] and serotonin 5-HT4 [32,33] as well
as the possible role of specific signalling pathways [34],
these receptor mutants suffered from high constitutive
activity and ligands which were able to interact with the
endogenous receptor subtype [35]. The second gener-
ation RASSLs have initially focused on muscarinic recep-
tors, where a high throughput yeast-based directed
evolution strategy generated an M3-muscarinic receptor
mutant that was not activated by the endogenous ligand,
acetylcholine, but was activated by clozapine-N-oxide
(CNO), a compound that otherwise had very low activity
at muscarinic receptors and other GPCR subtypes [36]
(Figure 2). By reverse engineering, Roth and colleagues
were able to introduce analogous mutations into the other
members of the muscarinic receptor family and generate
RASSL mutants responsive to CNO for the M1-M5www.sciencedirect.com
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generation muscarinic receptor RASSLs were called
‘Designer Receptors Exclusively Activated by Designer
Drug’ (DREADDs) and have proven useful in transgenic
mouse models aimed at determining signalling pathways
important in b-islet function [37,38], neuronal networks
involved in neurological responses such as locomotion
[39], learning and memory [40,41], limbic seizures
[39] and metabolism [42].
In tandem with this chemical genetic approach, have
been approaches that have generated mutant receptors
designed to determine the physiologically relevant sig-
nalling pathways that lay downstream of receptor acti-
vation. In these experiments, GPCR signalling is
considered to be bimodal, where signalling progresses
via heterotrimeric G-protein coupling or via receptor
phosphorylation and the recruitment of arrestin scaffold-
ing proteins [43]. By removal of receptor phosphorylation
sites, the receptor is less efficiently coupled to receptor
phosphorylation/arrestin dependent pathways relative to
coupling to G-protein activated pathways. In this way, the
receptor mutants lacking phospho-acceptor sites can be
considered as being G-protein biased [44,45]. Exper-
iments conducted in the author’s laboratory have focused
on the generation of a G-protein biased M3-muscarinic
receptor by the removal of 15 serine phospho-acceptor
sites in the third intracellular loop. This receptor was seen
to be reduced in its phosphorylation status and uncoupled
from arrestin and arrestin-dependent processes such as
receptor internalization [44,45]. The phosphorylation-
deficient receptor mutant was, however, seen to be
robustly coupled to Gq/11-protein pathways such as phos-
phoinositide hydrolysis and calcium signalling. By knock-
ing in this mutant sequence into the gene locus of the
wild type M3-muscarinic receptor a mutant mouse strain
was generated whereby the wild type M3-muscarinic
receptor was replaced by a mutant receptor [44,45].
Thus, as opposed to generating biased ligands and testing
the impact of these ligands on physiological responses, as
has been done for the angiotensin II type 1 receptor for
example [46–50], this approach generates a biased re-
ceptor. By monitoring the physiological phenotype of
these mutant mice it was possible to determine the
signalling modality employed in delivering a given re-
ceptor-mediated physiological response.
Employing transgenic animals expressing a G-
protein biased GPCR to determine
physiological signalling pathways
Thus, having generated a mouse mutant that expressed a
phosphorylation deficient version of the M3-muscarinic
receptor, the question was what impact did this mutation
have on muscarinic receptor-mediated physiological
responses? One response that was investigated was glu-
cose-dependent insulin secretion from b-cells of pancrea-
tic islets. Previous work, primarily from Jurgen Wess’www.sciencedirect.com laboratory, had determined that muscarinic receptor-
mediated augmentation of glucose dependent insulin
release was mediated by the M3-muscarinic receptor
[51–54]. Importantly, this augmentation occurs in both
the early and sustained phases of insulin release and
appears to have a number of regulatory elements. Cer-
tainly, there is an involvement of Gq/11-mediated calcium
mobilisation [55,56] which appears to be controlled, at
least in part, by spinophilin/RGS4 complex that limits the
lifetime of the activated Gaq/11-subunit [57]. The pro-
longed phase of insulin release was, however, significantly
diminished in b-cells isolated from mice expressing the
phosphorylation-deficient version of the M3-muscarinic
receptor [44]. This occurred despite the fact that both the
early and prolonged phases of calcium mobilisation in
these islets were robustly maintained [44]. Further exam-
ination revealed that the M3-muscarinic receptor in b-
cells was coupled to the atypical PKC-isomer, PKD1 [44].
This protein kinase was known from previous studies to
be important in mediating insulin vesicle fusion [58].
Removal of the phosphorylation sites on the M3-muscar-
inic receptor significantly decreased the coupling of the
receptor to PKD1 [44]. Furthermore, observations made
in other studies had implicated arrestin as important for
PKD1 activity [59]. Thus, it appears that the sustained
phase of insulin release observed in response to glucose
challenge can be augmented by M3-muscarinic receptors
in a manner that is mediated certainly by receptor phos-
phorylation mediated activation of PKD1 via a mechan-
isms that is possibly dependent on the recruitment of
arrestin [44] (Figure 3). In this way, the use of a G-protein
biased receptor expressed in mice has been used to
dissect the physiological functions of the bimodal signal-
ling pathways of the M3-muscarinic receptor.
Combining animal models to determine the
functional role of GPCRs and the
physiologically relevant signalling pathways
As described above, we now have a number of animal
models including transgenic knockouts, chemical
genetics and biased receptors that can be combined to
not only establish the physiological role and therapeutic
potential of any individual GPCR subtype, but also the
relevant signalling modality to be targeted. Can these
model animals therefore help in the design of the pharma-
cological properties of ligands to maximize clinical ef-
ficacy? It appears that the answer to this question may be
yes. Consider again the example of the M3-muscarinic
receptor where gene knockout studies have determined a
role in the control of insulin release [53] and chemical
genetics (i.e. an M3-muscarinic receptor DREADD
mutant) has defined the importance of Gq/11-signalling
in insulin release which [37], together with mutant mice
expressing a G-protein biased receptor, has determined
that the early phase of insulin release is primarily
mediated via Gq/11 signalling and the prolonged phase
via phosphorylation/arrestin signalling [44]. Based onCurrent Opinion in Cell Biology 2014, 27:117–125
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Introducing two specific orthosteric site mutations, one in transmembrane domain III and the other in transmembrane domain V, of muscarinic
receptors results in a reduced affinity for the natural ligand acetylcholine (ACh) and an increase in affinity for the otherwise inert chemical ligand
clozapine-n-oxide (CNO). This mutant receptor is called a DREADD. Shown is the example of the signalling of the wild type M1-muscarinic receptor
coupled to phosphoinositide pathway (measured as the accumulation of inositol phosphates (IPx)) following stimulation with acetylcholine or CNO
compared to the signalling of the M1-DREADD receptor mutant generated by an A–G and Y–C substitution. As can be seen, the M1-DREADD is
responsive to CNO and lacks a response to acetylcholine, whereas the wild type receptor shows no response to CNO but is fully activated by
acetylcholine.these studies we can make the following predictions; that
an M3-muscarinic receptor ligand that shows stimulus
bias towards G-protein coupling would preferentially
promote the early phase of insulin release and not the
prolonged phase. Conversely, an M3-muscarinic receptor
ligand that was biased towards receptor phosphorylation/
arrestin signalling would be expected to promote the
prolonged phase of insulin release over the early phase.
This observation is very important since one of the
features of the early stages of type 2 diabetes is the(Figure 1 Legend) Shown is a hypothetical example of a GPCR that is able t
signalling pathways. In the first example, ligand A is able to activate all three
ligand. In this case, ligand A shows no stimulus bias. In the second exampl
protein, which drives calcium mobilisation and subsequent smooth muscle 
ligand C drives signalling primarily via the pERK pathway, which leads to cell 
activate the Gq/11-protein pathway, whereas targeting the other two pathway
a Gq/11-protein biased ligand (i.e. ligand B) might represent the desired phar
lowest toxicity.
www.sciencedirect.com reduction in the early phase of insulin release [60,61].
Thus, an M3-muscarinic receptor specific ligand showing
bias to the G-protein signalling might be the desired
ligand to treat the dysfunction in the early phase of insulin
release observed in type 2 diabetes.
These mouse models can be extended further to predict
toxicity and adverse drug reaction. Knockout mice of the
M3-muscarinic receptor subtype have been used to estab-
lish an unexpected role for this receptor in learning ando mediate three physiological responses via the coupling to three distinct
 pathways with the same coupling efficiency as that seen for the natural
e, ligand B induces a receptor state that couples preferentially to Gq/11-
contraction. This ligand shows Gq/11-protein bias. In the final example,
growth. From a therapeutic perspective, it might be clinically beneficial to
s might lead to toxicity or adverse drug affects. If this were the case, then
macological properties of a drug to deliver maximal clinical efficacy with
Current Opinion in Cell Biology 2014, 27:117–125
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Figure 3
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The M3-muscarinic receptor expressed in b-islets of the pancreas is
involved in the augmentation of insulin release in response to increasing
concentrations of glucose. This response appears to be mediated by
two signalling pathways. The first is M3-receptor mediated signalling to
Gq/11-protein and calcium mobilisation, driving the early phase of insulin
release. The second sustained phase of insulin release phase is
dependent on receptor phosphorylation/arrestin mediated activation of
the atypical PKC, PKD1. Since type II diabetes is characterised by a
deficiency in the early phase of insulin release, it would seem that a
compound that targeted the M3-muscarinic receptor in a manner that
preferentially drove signalling through the Gq/11-protein pathway would
provide greatest clinical efficacy.memory [45]. Furthermore, use of the mutant mouse
expressing a G-protein biased receptor determined an
important role for receptor phosphorylation, and possibly
arrestin signalling in this response [45]. Integrating this
information with the features of the M3-muscarinic re-
ceptor mediated insulin release described above, one
might make the following prediction: that an M3-muscar-
inic receptor specific ligand displaying stimulus bias
towards receptor phosphorylation/arrestin signalling
might have properties that were beneficial in promoting
learning and memory. This same compound would likely
engage M3-muscarinic receptors expressed on b-islets,
but importantly, would not be expected to promote M3-
muscarinic receptor mediated early phase insulin
secretion since this response is largely mediated by
coupling to Gq/11 signalling. Thus, an M3-muscarinic
receptor ligand designed for maximal efficacy in learning
and memory, and thus showing stimulus bias towards
receptor phosphorylation/arrestin, would not be expected
to show a toxic/adverse response via muscarinic-mediated
early phase insulin release. However, any clinical trial
with such a molecule would have to determine that theCurrent Opinion in Cell Biology 2014, 27:117–125 molecule did not have adverse effects by promoting late
phase insulin release since this would be promoted by an
M3-muscarinic receptor ligand that was biased towards
receptor phosphorylation/arrestin signalling.
Conclusion: How might the animal models be
integrated with modern molecular
pharmacology to deliver on clinical efficacy
It is now the case that drug discovery programmes are
beginning to apply the sophisticated approaches
described here in the design of therapeutically active
GPCR ligands. This is most notable in heart failure where
chronic stimulation of G-protein signalling is considered
to be one of the contributing factors leading to cardio-
pathology [62,63]. Hence, antagonists of two key GPCRs
implicated in heart failure, namely the b1-adrenoceptor
and the angiotensin II type 1 receptor, have traditionally
been pursued with undoubted clinical success [64,65].
However, it is now clear that in addition to the inhibition
of G-protein signalling, it is desirable that ligands to these
two receptors are also able to activate arrestin signalling
which appears to provide cardioprotection [66]. Thus,
biased ligands to both the b1-adrenoceptor and the angio-
tensin II type 1 receptor, where the ligands act as an
antagonists (or even inverse agonists) at G-protein signal-
ling but are agonists at arrestin signalling is now con-
sidered the ideal ligand to provide maximum therapeutic
efficacy in the chronic treatment of heart failure
[49,64,67].
Thus, in heart failure, and other diseases, it will be
important to revisit the screening of ligands to develop
novel ligands that have newly defined, desirable, pharma-
cological properties. An important factor in the search for
these novel ligands is the growing list of crystal structures
[2] for GPCRs which provides the opportunity to
incorporate in silico screening and structure-based drug
design as an approach to screen and develop GPCR
ligands[2,68]. These approaches have certainly been
applied to a number of commercial screening programmes
as well as screening programmes in academic laboratories
[69,70,71]. However, structure-based screening
methods are still restricted as most of the GPCR struc-
tures currently available are in an inactive conformation
and have been resolved with orthosteric and not allosteric
ligands. Nonetheless, the publication of the first active
structures of non-visual GPCRs [72,73,74] and the de-
velopment of mutant receptors stabilised in the partially
active conformation [75], together with the application of
molecular dynamics to map the interaction of ligands at
both orthosteric and allosteric sites [72,76–78], means that
we are racing towards a time where in silico docking and
structure-based methods can be readily applied to the
development of pharmacological ligands. These new
approaches will undoubtedly be used in combination
with sophisticated transgenic and chemical genetic
animal models to facilitate design of ligands with thewww.sciencedirect.com
Novel GPCR mouse models Bradley, Riaz and Tobin 123desired pharmacological properties required to deliver a
therapeutic response. By combining these approaches,
the next generation of GPCR ligands will unquestionably
be more sophisticated, employing rational design prin-
ciples to deliver GPCR ligands with low toxicity with
maximal clinical efficacy.
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